Lite Strategy Inc. – Material Contracts Watch

from 8-K 20 pages Lite Strategy, Inc. 2026 Stock Omnibus Equity Compensation Plan Effective as of February 12, 2026

from 8-K 8 pages Lite Strategy, Inc. Employee Proprietary Information and Intellectual Property Agreement

from 8-K 15 pages December 23, 2025 Dear Justin, This Employment Agreement (This “Agreement”), Effective as of November 14, 2025 (The “Effective Date”), Confirms the Terms of Your Employment With Lite Strategy, Inc. (Formerly Known as Mei Pharma, Inc., the “Company”)

from 8-K 6 pages Strategic Advisor Agreement

from 8-K 7 pages Advisory Agreement

from 8-K 2 pages July 22, 2025 Gsr Strategies LLC C/O Corporation Service Company 251 Little Falls Drive, Wilmington, De 19808 Email: LEGAL@GSR.IO; TRADING-OPS@GSR.IO Attn: Legal & Compliance Re: Side Letter - Board Nominee Right Ladies and Gentlemen,

from 8-K 31 pages Asset Management Agreement

from 8-K 17 pages Registration Rights Agreement

from 8-K 8 pages Placement Agency Agreement

from 8-K 31 pages Securities Purchase Agreement

from 8-K 10 pages March 3, 2025 Dear Justin, This Amended and Restated Employment Agreement (This “Agreement”), Effective as of March 3, 2025 (The “Effective Date”), Confirms the Terms of Your Employment With MEI Pharma, Inc. (“Mei”). Whereas, You Are Currently Employed by MEI Pursuant to the Terms of the Letter Agreement, Effective June 12, 2023, as Amended by the Addendum, Dated July 31, 2024 (The “Prior Agreement”); and Whereas, You and MEI Have Determined That It Is in the Best Interest of MEI and You to Amend and Restate the Prior Agreement, Which Is Hereby Superseded in Its Entirety, Effective as of the Effective Date. Now, Therefore, in Consideration of the Mutual Promises and Undertakings Herein Contained, and Intending to Be Legally Bound Hereby, You and MEI Agree as Follows: 1

from 10-Q 9 pages Consulting Services Agreement Amended September 13, 2024

from 10-Q 9 pages Consulting Services Agreement Amended September 13, 2024

from 10-Q 12 pages Separation and Release Agreement

from 10-Q 12 pages Separation and Release Agreement

from 10-K 4 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential

from 10-Q 21 pages MEI Pharma, Inc. Amended and Restated 2008 Stock Omnibus Equity Compensation Plan Effective as of December 18, 2023

from 10-Q 13 pages Material contract

from 8-K 30 pages Cooperation Agreement

from 10-K 15 pages Form of Warrant